Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C36H72NO8P |
Molecular Weight | 677.9325 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC
InChI
InChIKey=CITHEXJVPOWHKC-UUWRZZSWSA-N
InChI=1S/C36H72NO8P/c1-6-8-10-12-14-16-18-20-22-24-26-28-35(38)42-32-34(33-44-46(40,41)43-31-30-37(3,4)5)45-36(39)29-27-25-23-21-19-17-15-13-11-9-7-2/h34H,6-33H2,1-5H3/t34-/m1/s1
DescriptionCurator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/10866960 | http://www.sciencedirect.com/science/article/pii/S1818087614000725
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/10866960 | http://www.sciencedirect.com/science/article/pii/S1818087614000725
1,2-DIMYRISTOYL-SN-GLYCERO-3-PHOSPHOCHOLINE (dimyristoyl phosphatidylcholine, DMPC) is a synthetic phospholipid used in liposomes and lipid bilayers for the study of biological membranes. DMPC is a frequently studied artificial lipid because it undergoes a phase transition at a convenient temperature. Upon cooling below
23.6°C it undergoes a transition from the liquid crystalline phase to the solid rippled phase, characterized by periodic corrugations of the
bilayer.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL5984 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Inactive ingredient | ABELCET Approved UseABELCET is indicated for the treatment of invasive fungal infections in patients who are refractory to or intolerant of conventional amphotericin B therapy. This is based on open-label treatment of patients judged by their physicians to be intolerant to or failing conventional amphotericin B therapy Launch Date1.28735995E12 |
|||
Diagnostic | IMAGENT Approved UseReconstituted Imagent (Perflexane Lipid Microspheres) Injectable Suspension is indicated
for use in subjects with suboptimal echocardiograms to opacify the left ventricular chamber
and to improve the delineation of the left ventricular endocardial border Launch Date1.02271681E12 |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
300 mg/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31776208/ |
33 mg/kg single, intravenous dose: 33 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
PHOSPHOLIPIDS plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
703.2 mg × h/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31776208/ |
33 mg/kg single, intravenous dose: 33 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
PHOSPHOLIPIDS plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31776208/ |
33 mg/kg single, intravenous dose: 33 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
PHOSPHOLIPIDS plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
PubMed
Title | Date | PubMed |
---|---|---|
Interaction of human and bovine A-1 apolipoproteins with L-alpha-dimyristoyl phosphadicylcholine and L-alpha-myristoyl lysophosphatidylcholine. | 1977 Apr 10 |
|
Physical properties of isolated complexes of human and bovine A-I apolipoproteins with L-alpha-dimyristoyl phosphatidylcholine. | 1977 Apr 10 |
|
Antibodies to liposomal phosphatidylcholine and phosphatidylsulfocholine. | 1990 Jan |
|
Selective inhibitory effects of hybrid liposomes on the growth of HIV type 1-infected cells in vitro. | 2008 Aug 15 |
|
Synthetic dimyristoylphosphatidylcholine liposomes assimilating into high-density lipoprotein promote regression of atherosclerotic lesions in cholesterol-fed rabbits. | 2010 Oct |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20876082
Cholesterol-fed rabbits infused weekly with dimyristoylphosphatidylcholine (DMPC) liposomes (300 mg/kg body weight) for five weeks had significantly decreased aortic cholesterol contents compared with saline-infused cholesterol-fed controls. Atherosclerotic plaque volume, as measured by a type of new magnetic resonance imaging analysis, also decreased significantly after DMPC treatment.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18672367
Curator's Comment: A good correlation between fifty-percent inhibitory concentration (IC(50)) of hybrid liposomes (HL) composed of dimyristoylphosphatidylcholine and polyoxyethylene(n) dodecyl ether on the growth of MOLT-4/IIIB cells (MOLT-4 cells chronically infected with human immunodeficiency virus (HIV)) and the membrane fluidity of HL was obtained.
Unknown
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C927
Created by
admin on Fri Dec 15 15:52:09 UTC 2023 , Edited by admin on Fri Dec 15 15:52:09 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5459377
Created by
admin on Fri Dec 15 15:52:09 UTC 2023 , Edited by admin on Fri Dec 15 15:52:09 UTC 2023
|
PRIMARY | |||
|
242-085-9
Created by
admin on Fri Dec 15 15:52:09 UTC 2023 , Edited by admin on Fri Dec 15 15:52:09 UTC 2023
|
PRIMARY | |||
|
Dimyristoylphosphatidylcholine
Created by
admin on Fri Dec 15 15:52:09 UTC 2023 , Edited by admin on Fri Dec 15 15:52:09 UTC 2023
|
PRIMARY | |||
|
DTXSID00860227
Created by
admin on Fri Dec 15 15:52:09 UTC 2023 , Edited by admin on Fri Dec 15 15:52:09 UTC 2023
|
PRIMARY | |||
|
52QK2NZ2T0
Created by
admin on Fri Dec 15 15:52:09 UTC 2023 , Edited by admin on Fri Dec 15 15:52:09 UTC 2023
|
PRIMARY | |||
|
CHEMBL1201501
Created by
admin on Fri Dec 15 15:52:09 UTC 2023 , Edited by admin on Fri Dec 15 15:52:09 UTC 2023
|
PRIMARY | |||
|
45240
Created by
admin on Fri Dec 15 15:52:09 UTC 2023 , Edited by admin on Fri Dec 15 15:52:09 UTC 2023
|
PRIMARY | |||
|
18194-24-6
Created by
admin on Fri Dec 15 15:52:09 UTC 2023 , Edited by admin on Fri Dec 15 15:52:09 UTC 2023
|
PRIMARY | |||
|
C61726
Created by
admin on Fri Dec 15 15:52:09 UTC 2023 , Edited by admin on Fri Dec 15 15:52:09 UTC 2023
|
PRIMARY |
ACTIVE MOIETY